Integer™

3Q16 Earnings Conference Call

October 27, 2016

Greatbatch Medical | Lake Region MEDICAL | ELECTROCHEM

Presentation of Financial Information & Forward Looking Statements

Historical financial and operating data in this presentation reflect the consolidated results of Integer for the periods indicated.

This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include Adjusted Net Income, Adjusted Diluted EPS, Earnings Before Interest Taxes Depreciation and Amortization (EBITDA), and Adjusted EBITDA, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of these non-GAAP financial measures to the most comparable GAAP measures, please refer to the appendix to this presentation and the earnings release associated with this quarterly period which can be found in the investor relations section of our corporate website (www.integer.net).

Statements made in this presentation whether written or oral may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of Securities Exchange Act of 1934, as amended, and involve a number of risks and uncertainties. These statements can be identified by terminology such as "may," "will," "should," "could," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or "variations" or the negative of these terms or other comparable terminology. These statements are based on the company's current expectations and speak only as of **October 27, 2016**. The Company's actual results could differ materially from those stated or implied by such forward-looking statements. The Company assumes no obligation to update forward-looking information, including information in this presentation, to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects.

Agenda

- Opening Comments
- Financial Results
- Product Line Review
- Strategic / Growth Initiatives
- Closing Comments
- Question & Answer Period

Thomas J. Hook
President & CEO

Michael Dinkins
Executive Vice President
& Chief Financial Officer

Opening Comments

Quarterly Results Reflect Progress, More Work to Do

"We have established improved line of sight into our customers' programs, demand plans and growth objectives which will help us better manage our business and product line forecasts even further."

- Leveraging customer relationships
  - Improved line of sight into customer programs, demand plans and growth objectives.
- Operationally, making progress
  - Cost reduction initiatives generating results
  - Successfully extending payment terms with many key supply chain partners
  - Remain focused on working capital
- Financial performance stabilizing
  - 3Q16 revenue flat YoY and QoQ
  - Quarterly improvement in gross margin and operating costs
  - Generating increased cash flow from operations

Financial Results

3Q16 Key Financial Results[1]

($ in millions, except per share amounts)	3Q15	2Q16	3Q16
Sales	$ 348	$ 348	$ 347
Gross Margin	*28.2%*	*27.6%*	*28.3%*
Operating Expenses	$ 74	$ 67	$ 61
% of Sales	*21.2%*	*19.2%*	*17.6%*
GAAP Net Income	$ (5)	$ (1)	$ 11
Adjusted Net Income	$ 20	$ 18	$ 26
EBITDA	$ 51	$ 51	$ 59
Adjusted EBITDA	$ 73	$ 69	$ 75
% of Sales	*21.1%*	*19.8%*	*21.6%*
GAAP Diluted EPS	$ (0.15)	$ (0.03)	$ 0.37
Adjusted Diluted EPS	$ 0.64	$ 0.56	$ 0.83
Cash Flow from Operations		$ 4	$ 38

- Revenue stabilizing YoY and QoQ
- Cost reduction initiatives coupled with accelerated integration synergies are producing results
- Adjusted EBITDA margins improved 50 bps YoY and 180bps QoQ
- Remain focused on improving working capital to increase cash flow and ability to pay down debt

(1) 3Q16 Key Financial Results provided on a comparable basis. Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation ("Nuvectra") prior to its spin-off on March 14, 2016. Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical. Historical pro forma information, which was filed with the SEC on Form 8-K on February 29, 2016, contains a reconciliation of 2015 comparable amounts to as reported amounts.

Sales Stabilizing Across Multiple Product Lines

Quarterly Sales[1]

($ in millions)



3Q16 Sales

	YoY	QoQ	YTD
Total Sales	(0.5%)	(0.5%)	(5.3%)
Electrochem	(26%)	(10%)	(34%)
Adv. Surgical, Ortho & Portable Medical	(4%)	(9%)	(7%)
Cardiac/Neuro	2%	5%	(6%)
Cardio & Vascular	1%	3%	(1%)

(1) Sales information provided on a comparable basis. Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation ("Nuvectra") prior to its spin-off on March 14, 2016. Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical. Historical pro forma information, which was filed with the SEC on Form 8-K on February 29, 2016, contains a reconciliation of 2015 comparable amounts to as reported amounts.

(2) Total sales includes the sum of sales for each of ITGR's product lines, as detailed on this slide and the elimination of Interproduct Line Sales, for which amounts are not included on this slide.

Adjusted EBITDA

Adjusted EBITDA[1]

($ in millions)



	4Q15	1Q16	2Q16	3Q16
% of Sales	22%	20%	20%	22%

- Focused on improving business performance to generate cash
  - Ongoing pricing pressure reinforces focus on quality to drive volume increases and efficiency
  - Improve customer satisfaction
  - Reduce costs and expand share of wallet with customers
- Excludes $13.9M of OOE and IP related litigation expenses in 3Q16[2]
- Integration plan ahead of schedule, continue to expect FY16 net synergies in excess of original targets

(1) Adjusted EBITDA provided on a comparable basis. Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation ("Nuvectra") prior to its spin-off on March 14, 2016. Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical. Historical pro forma information, which was filed with the SEC on Form 8-K on February 29, 2016, contains a reconciliation of 2015 comparable amounts to as reported amounts.

(2) See APPENDIX for additional information regarding Other Operating Expenses (OOE), including historical data.

Generating Cash to Accelerate Debt Repayment





- Generating significant cash flow to meet current debt obligations and accelerate debt repayments
  - Focused on reducing total leverage as quickly as possible
  - Paid down $12M of debt in 3Q16; $29M YTD
- Total long-term debt of $1.7B as of September 2016
  - No significant maturities until 2020
  - Mitigating exposure to interest rate volatility
- Operating business to maintain compliance with Financial Covenants(2)

(1) Free Cash Flow defined as Cash from Operations less Capital Expenditures

(2) See the APPENDIX to this presentation for further discussion regarding financial covenant calculations

Effectively Managing Working Capital

($ in millions)	1Q16	2Q16	3Q16
Inventory	$252	$276	$262
Inventory Turns	4	4	4
Capital Expenditures	$19	$12	$17

Working Capital

($ in millions)



- Maintaining focus on increased cash flows through working capital management and improved operational execution
  - Targeting continued reduction in inventory levels throughout 2016 and 2017
  - Rationalizing vendor partners to drive synergies and extend payment terms
  - On-going process improvement programs to reduce direct materials spend and indirect expenses

FY 2016 Outlook

($ in millions, except per share amounts)	1Q16 Actual	2Q16 Actual	3Q16 Actual	FY16 Outlook
Revenue	$331	$348	$347	$1,375 - $1,395
Adjusted:				
EBITDA	$65	$69	$75	$285 - $295
Net Income	$13	$18	$26	$82 - $86
Diluted EPS	$0.42	$0.56	$0.83	$2.60 - $2.75
Net Synergies	$5	$8	$10	$30 - $35

- Capital Expenditures expected to be in the range of $55M - $60M per year
- Depreciation & Amortization expected to be in the range of $85M - $95M in FY16
- Stock Compensation Expense expected to be ~$9M in FY16
- Working Capital expected to improve $25M - $50M by YE2016
- FY16 Adjusted Effective Tax Rate expected to be 25% - 30%.
  - Cash Taxes expected to be ~$8M in FY16
- Other Operating Expense expected to be in the range of $55M - $65M in FY16

Product Line Review

Advanced Surgical, Orthopedics & Portable Medical

Providing a wide range of technologies and solutions to the Advanced Surgical and Orthopedic markets

Implants

Delivery Systems

Reamers

Laparoscopic Devices

Arthroscopy Products

- Revenue remains a solid contributor to total Company results
- Significant progress with Wireless Initiative during quarter, driving active programs and further engagement with our strategic customers
- Steady operational performance driven by improvements in customer relationships
- Multiple continuous improvement initiatives in place across our operations – early results are positive
- New product launches and acceleration in targeted areas expected to drive slight revenue growth in 2017

Cardio & Vascular

Offering a full-range of products and services for catheter-based interventional vascular devices and a suite of supply chain solutions to support the development and manufacturing of complex components, sub-assemblies and finished devices



Steerable Sheaths



Catheters & Sheaths



Guidewires, Stylets & Accessories

Introducers

- 3Q16 Revenue increased 1% YoY and 3% QoQ
- Operational performance backed by strong customer relationships
- Key customer program to commence commercialization late in 4Q16, will ramp throughout 2017
- Multiple opportunities to win new program and drive future revenue growth
- Focused on remaining our customers' partner of choice

Cardiac / Neuromodulation

Providing technology solutions for the active implantable medical device industry by partnering with customers to bring quality products to established and emerging markets - from initial concept through to high volume manufacturing

Batteries

Feedthroughs

Enclosures

Coated Electrodes

Full System Solutions

- Revenue is stabilizing with visibility to revenue growth opportunities
- New product development and manufacturing programs in place with leading medical device manufacturers, identified additional targets
- Actively seeking contract extensions with our customers, successfully signed 5-year and 10-yr extensions with two key customers
- Focused on decreasing total cost of ownership for our customers by leveraging our combined capabilities
- Driving operational excellence and enhancing our customer-centric culture

Electrochem

Enhancing lives worldwide by providing superior power solutions that enable the success and advancement of our customers' critical applications

Battery Cells

Battery Packs

Battery Chargers

- Revenues continue to trend with Oil & Gas market
  - Believe market has bottomed, signs of a slow recovery
- Military and Environmental customer volumes remain steady
- Growing market share within the space
- Strong customer relationships across all market segments, driven by operational and quality performance
- Advancing competitive position through multi-year supply agreements
- Actively pursuing new customer and market opportunities

Strategic / Growth Initiatives

Key Strategic Focus Areas

"Our vision is to enhance the lives of patients worldwide by being our customers' partner of choice for innovative technologies and services."

- Invest to drive growth across full spectrum of product and systems capabilities
  - Focused on improving and enhancing customer relationships
  - Development programs underway across all product categories
- Deliver shareholder returns through growth in profitability and cash generation
  - Accelerate repayment of debt obligations
  - Productivity initiatives in place to reduce direct and indirect spend
- Optimize the commitment and contribution of our Associates by cultivating an ethical, values-driven culture

Closing Comments

Well-Positioned for Future Growth

Broad Product Continuum

Strong Customer Relationships

Operating & Manufacturing Scalability

Innovation Pipeline to Enable Customer Success

Business Optimization Driving Strong Cash Generation

Question & Answer Period

APPENDIX

Debt – Financial Covenant Calculations

Financial Covenant Calculations[1][2]

Leverage Ratio (< 6.5 @ 3Q16)

Leverage Ratio = Net Debt / R12 Bank EBITDA

Interest Coverage Ratio (> 3.00 @ 3Q16)

Interest Coverage Ratio = R12 Bank EBITDA / R12 Cash Interest Expense[3]

Net Debt

Net DEBT = Total Debt - Cash & Cash Equivalents (not to exceed $50M)

Bank EBITDA

R12 Bank EBITDA = R12 Adjusted EBITDA + Future Synergies and Cost Savings[4]

(1) Financial Covenant ratios adjust in future reporting periods. Details are available in ITGR's publicly filed credit agreements

(2) R12 = Rolling 12 months

(3) R12 Cash Interest Expense excludes debt related amortization amounts included in Interest Expense

(4) Future Synergies and Cost Savings

- At the end of each fiscal quarter, Integer can add the planned impact of synergies and cost savings initiatives connected to the Lake Region acquisition for the next twelve months.
- These are calculated on a pro forma basis assuming they had been in effect at the beginning of the test period.
- Synergies may include the incremental Adjusted EBITDA impact of revenue synergies. These would be new revenue initiatives that are specifically enabled by the merger.
- Synergies are limited to a maximum of $35 million. The allowable adjustment changes over time beginning in 2017

Other Operating Expenses

	Three Months Ended			Nine Months Ended		
	10/2/15	7/1/16	9/30/16	10/2/15	9/30/16	NOTES:
2014 Investments in Capacity and Capabilities	$5.1	$5.1	$4.5	$17.9	$13.8	Portable Medical and Vascular product line transfers
Orthopedic Facilities Optimization	$0.4	$0.2	$0.3	$1.3	$0.6	
Legacy Lake Region Medical Consolidation and Optimization	--	$2.1	$2.9	$0.0	$7.4	
Acquisition and Integration Costs	$5.2	$7.9	$5.3	$5.4	$23.1	Lake Region Medical and CCC Medical Devices
Asset Dispositions, Severance, and Other	$3.2	$0.3	$0.3	$4.9	$5.1	Nuvectra spin-off
Comparable Basis Adjustments, net[1]	$5.3	--	--	$14.7	($1.1)	
TOTAL OOE	**$19.2**	**$15.5**	**$13.4**	**$44.2**	**$48.9**	

(1) Details of Other Operating Expenses (OOE) provided on a comparable basis. Comparable basis amounts for 2016 exclude the results of Nuvectra Corporation ("Nuvectra") prior to its spin-off on March 14, 2016. Comparable basis amounts for 2015 exclude the results of Nuvectra and include the results of the former Lake Region Medical. Historical pro forma information, which was filed with the SEC on Form 8-K on February 29, 2016, contains a reconciliation of 2015 comparable amounts to as reported amounts.

Non-GAAP Reconciliation

Net Income and Diluted EPS Reconciliation – QTD

($ in thousands except per share amounts)	Three Months Ended					
	September 30, 2016			October 2, 2015		
	Pre-Tax	Net Income	Per Diluted Share	Pre-Tax	Net Income	Per Diluted Share
Income and diluted EPS as reported (GAAP)	$ 8,717	$ 11,458	$ 0.37	$ 6	$ 22	$ —
Adjustments:						
Amortization of intangibles[a]	9,473	6,702	0.22	3,243	2,271	0.09
IP related litigation (SG&A)[a][b]	499	324	0.01	1,127	733	0.03
Consolidation and optimization expenses (OOE)[a][c]	7,779	6,409	0.21	5,473	4,523	0.17
Acquisition and integration expenses (OOE)[a][d]	5,319	3,492	0.11	5,202	4,845	0.18
Asset dispositions, severance and other (OOE)[a][e]	272	36	—	3,169	2,468	0.09
Lake Region Medical transaction costs (interest expense)[a][f]	—	—	—	4,788	3,112	0.12
Loss (gain) on cost and equity method investments, net (other expense (income), net)[a]	245	159	0.01	(4,579)	(2,976)	(0.11)
Tax adjustments[g]	—	(2,784)	(0.09)	—	400	0.02
Taxes[a]	(6,508)	—	—	(3,031)	—	—
As reported adjusted net income and diluted EPS (Non-GAAP)	25,796	25,796	0.83	15,398	15,398	0.58
Comparable basis adjustments, net[h]	—	—	—	4,793	4,793	0.06
Comparable basis net income and diluted EPS (Non-GAAP)	$ 25,796	$ 25,796	$ 0.83	$ 20,191	$ 20,191	$ 0.64
As reported adjusted diluted weighted average shares			31,153			26,441
Comparable basis diluted weighted average shares[i]			31,153			31,481

See the Footnotes to this table on Slide 28 of this presentation

Non-GAAP Reconciliation

Net Income and Diluted EPS Reconciliation – YTD

($ in thousands except per share amounts)	Nine Months Ended					
	September 30, 2016			October 2, 2015		
	Pre-Tax	Net Income	Per Diluted Share	Pre-Tax	Net Income	Per Diluted Share
Income (loss) and diluted EPS as reported (GAAP)	$ (3,358)	$ (1,972)	$ (0.06)	$ 21,761	$ 17,313	$ 0.66
Adjustments:						
Amortization of intangibles[a]	28,451	20,125	0.64	10,008	6,996	0.27
IP related litigation (SG&A)[a][b]	2,691	1,749	0.06	3,286	2,136	0.08
Consolidation and optimization expenses (OOE)[a][c]	21,804	17,698	0.57	19,202	15,422	0.58
Acquisition and integration expenses (OOE)[a][d]	23,143	15,148	0.49	5,366	4,961	0.19
Asset dispositions, severance and other (OOE)[a][e]	5,057	4,459	0.14	4,881	3,600	0.14
Lake Region Medical transaction costs (interest expense)[a][f]	—	—	—	4,788	3,112	0.12
Gain on cost and equity method investments, net (other expense (income), net)[a]	(932)	(606)	(0.02)	(5,119)	(3,327)	(0.13)
Tax adjustments[g]	—	(2,784)	(0.09)	—	1,200	0.05
Taxes[a]	(23,039)	—	—	(12,760)	—	—
As reported adjusted net income and diluted EPS (Non-GAAP)	53,817	53,817	1.72	51,413	51,413	1.95
Comparable basis adjustments, net[h]	2,624	2,624	0.08	18,904	18,904	0.29
Comparable basis net income and diluted EPS (Non-GAAP)	$ 56,441	$ 56,441	$ 1.81	$ 70,317	$ 70,317	$ 2.24
As reported adjusted diluted weighted average shares[j]			31,211			26,372
Comparable basis diluted weighted average shares[i][j]			31,211			31,364

See the Footnotes to this table on Slide 28 of this presentation

Non-GAAP Reconciliations

Footnotes to "Net Income and Diluted EPS Reconciliation"

(a) The difference between pre-tax and net income amounts is the estimated tax impact related to the respective adjustment. Net income amounts are computed using a 35% U.S., Mexico, Germany, and France statutory tax rate, a 0% Swiss tax rate, a 20% Netherlands statutory tax rate, a 25% Uruguay statutory tax rate, and a 12.5% Ireland statutory tax rate. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

(b) In 2013, we filed suit against AVX Corporation alleging they were infringing our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, we are excluding these litigation expenses from adjusted amounts. This matter proceeded to trial during the first quarter of 2016 and a federal jury awarded the Company $37.5 million in damages. To date, no gains have been recognized in connection with this litigation.

(c) During 2016 and 2015, we incurred costs primarily related to the transfer of our Beaverton, OR, portable medical and Plymouth, MN, vascular manufacturing operations to Tijuana, Mexico. Additionally, with the acquisition of Lake Region Medical, 2016 costs also include expenses incurred in connection with the closure of Lake Region Medical's Arvada, CO, site and the consolidation of its two Galway, Ireland sites, which was initiated by Lake Region Medical in 2014.

(d) During 2016 and 2015, we incurred acquisition and integration costs related to the acquisition of Lake Region Medical, which was acquired in October 2015. During 2015, we incurred costs related to the integration of CCC Medical Devices, which was acquired in August 2014.

(e) Costs primarily include legal and professional fees incurred in connection with the spin-off of Nuvectra, which was completed in March 2016.

(f) During the third quarter of 2015, we recorded transaction costs (i.e. debt commitment fees, interest rate swap termination costs) in connection with our acquisition of Lake Region Medical.

(g) Tax adjustments for the 2016 periods include a discrete tax benefit related to certain transaction costs of the Lake Region Medical acquisition and the spin-off of Nuvectra. For the 2015 periods, tax adjustments consist of the 2015 Federal R&D tax credit, which was enacted during the fourth quarter of 2015 and has been permanently reinstated. Amounts assume that the tax credit was effective at the beginning of the year for 2015.

(h) Comparable basis adjustments for the year-to-date 2016 period represents the exclusion of the results of Nuvectra prior to its spin-off on March 14, 2016. Comparable basis adjustments for 2015 periods represents the exclusion of the Nuvectra results and the inclusion of the former Lake Region Medical results. Our historical pro forma information presentation, which was filed with the SEC on Form 8-K on February 29, 2016, contains a reconciliation of 2015 comparable basis amounts to as reported amounts.

(i) Comparable basis diluted weighted average shares for the 2015 periods include shares issued in conjunction with the acquisition of Lake Region Medical as if the acquisition occurred at the beginning of the period. No adjustment is necessary for the 2016 periods, as shares issued for the acquisition are included in the Company's outstanding shares in accordance with GAAP.

(j) The as reported adjusted diluted weighted average shares and the comparable basis diluted weighted average shares for the year-to-date 2016 period includes 455,000 potentially dilutive shares not included in the computation of diluted weighted average common shares for GAAP diluted EPS purposes because their effect would have been anti-dilutive given the Company's net loss.

Non-GAAP Reconciliations

Adjusted EBITDA Reconciliation

($ in thousands)	Three Months Ended		Nine Months Ended	
	September 30, 2016	October 2, 2015	September 30, 2016	October 2, 2015
Net income (loss) as reported (GAAP)	$ 11,458	$ 22	$ (1,972)	$ 17,313
Interest expense	27,870	5,825	83,395	8,151
Provision (benefit) for income taxes	(2,741)	(16)	(1,386)	4,448
Depreciation	12,893	5,504	38,963	16,933
Amortization	9,473	3,243	28,451	10,008
EBITDA	58,953	14,578	147,451	56,853
IP related litigation	499	1,127	2,691	3,286
Stock-based compensation	1,950	3,027	5,773	8,999
Consolidation and optimization expenses	7,779	5,473	21,804	19,202
Acquisition and integration expenses	5,319	5,202	23,143	5,366
Asset dispositions, severance and other	272	3,169	5,057	4,881
Noncash (gain) loss on cost and equity method investments	245	(1,178)	(270)	(1,718)
As reported adjusted EBITDA (Non-GAAP)	75,017	31,398	205,649	96,869
Comparable basis adjustments[(a)]	—	42,070	3,665	128,393
Comparable basis adjusted EBITDA (Non-GAAP)	$ 75,017	$ 73,468	$ 209,314	$ 225,262
Adjusted EBITDA as a % of sales	21.6%	21.4%	20.0%	20.1%
Comparable basis adjusted EBITDA as a % of sales	21.6%	21.1%	20.4%	20.8%

(a) Comparable basis adjustments for the year-to-date 2016 period represents the exclusion of the results of Nuvectra prior to its spin-off on March 14, 2016. Comparable basis adjustments for the 2015 periods represents the exclusion of the Nuvectra results and the inclusion of the former Lake Region Medical results. Our historical pro forma information presentation, which was filed with the SEC on Form 8-K on February 29, 2016, contains a reconciliation of 2015 comparable basis amounts to as reported amounts.

Non-GAAP Reconciliations

2016 Full-Year Outlook

($ in millions, except per share amounts)	GAAP		Adjusted Comparable Basis	
	High	**Low**	**High**	**Low**
Revenue	$1,396	$1,376	$1,395	$1,375
Net Income	$13	$9	$86	$82
Earnings per Diluted Share	$0.42	$0.27	$2.75	$2.60
EBITDA	n/a	n/a	$295	$285

Except as described below, further reconciliations by line item to the closest corresponding GAAP financial measures for Adjusted Comparable Basis Net Income, Adjusted Comparable Basis Earnings per Diluted Share, and Adjusted EBITDA, included in our “Full-Year 2016 Sales and Earnings Outlook” above, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from these non-GAAP financial measures.

Comparable Basis Adjusted Net Income and EPS for 2016 are expected to consist of GAAP Net Income and EPS, excluding items such as intangible amortization (approximately $40 million), IP related litigation costs, and consolidation, acquisition, integration, and asset disposition/write-down charges totaling approximately $105 million. The after-tax impact of these items is estimated to be approximately $70 million, or approximately $2.25 per diluted share. Additionally, our comparable basis revenue, adjusted effective tax rate, adjusted net income, adjusted diluted EPS and adjusted EBITDA guidance excludes the results of Nuvectra prior to its spin-off on March 14, 2016, of $1.2 million, a tax benefit of $1.4 million, a loss of $2.6 million, a loss of $0.08 per share, and $3.7 million of adjusted EBITDA, respectively. EBITDA is a non-GAAP measure that is based on net income further excluding taxes, interest, depreciation and amortization.

Contact Information

Amy Wakeham
VP, Investor Relations

Integer
ir@greatbatch.com
(O) 214.618.4978
(M) 214.430.7208

www.integer.net